Expert Practice℠ in Pancreatic Cancer
prIME Downloadable Slides
prIME Downloadable Slides

Expert Practice℠ in Pancreatic Cancer

Not a member of My prIME? Join now for instant access.

Explore the latest updates on molecular biology, imaging, and current standard of care in resectable, unresectable, and metastatic pancreatic cancer with these downloadable slides presented at our Expert Practice℠ in Pancreatic Cancer meeting.

Downloadable Slides

Downloadable Slides

IME

IME

Release Date

Release Date

Oct 5, 2017

Expiration Date

Oct 5, 2018

Featured Expert

  • Eric Van Cutsem, MD, PhD, University Hospitals Leuven, Leuven, Belgium

Featured Topic

Setting the stage: Key milestones and challenges in the management of pancreatic cancer

Featured Experts

  • Christiane Bruns, MD, PhD, University of Cologne, Cologne, Germany

Featured Topic

Hot topic debate: Should every patient with resectable pancreatic cancer receive upfront chemotherapy?–YES

Featured Experts

  • Gabriela Chiorean, MD, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Featured Topic

Hot topic debate: Should every patient with resectable pancreatic cancer receive upfront chemotherapy?–NO

Featured Expert

  • Volker Ellenrieder, MD, PhD, University Hospital Gӧttingen, Gӧttingen, Germany

Featured Topic

Keynote Lecture 1—Advances in molecular biology of pancreatic cancer: Understanding genetic complexity and molecular heterogeneity

Featured Expert

  • Maria Antonietta Bali, MD, PhD, Institut Jules Bordet, Free University of Brussels, Brussels, Belgium

Featured Topic

Imaging of pancreatic cancer: Current state of the art and future trends

Featured Expert

  • Christiane Bruns, MD, PhD, University of Cologne, Cologne, Germany

Featured Topic

Case #1—Resectable pancreatic ductal carcinoma
Part I: Advances in surgery

Featured Expert

  • Teresa Macarulla, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain

Featured Topic

Case #1—Resectable pancreatic ductal carcinoma
Part II: Current and emerging adjuvant therapies
Part III: Managing borderline resectable pancreatic cancer and follow-up strategies

Featured Expert

  • Stefano Cascinu, MD, PhD, University of Modena and Reggio Emilia, Modena, Italy

Featured Topic

Case #2—Locally advanced unresectable pancreatic cancer: Evaluating treatment options

Featured Expert

  • Gabriela Chiorean, MD, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Featured Topic

Keynote Lecture 2—Targeting the tumor microenvironment in pancreatic cancer

Featured Expert

  • Philip Agop Philip, MD, PhD, FRCP, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan, United States

Featured Topic

Case #3—Metastatic pancreatic ductal adenocarcinoma: Selecting an optimal first-line approach

Featured Expert

  • Gerald Prager, MD, Medical University of Vienna, Vienna, Austria

Featured Topic

Case #4—Progressive pancreatic cancer: Optimal sequencing of systemic therapy?

Featured Expert

  • Philip Agop Philip, MD, PhD, FRCP, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan, United States

Featured Topic

Pancreatic cancer management in the coming year: What can we expect?

Featured Expert

  • Eric Van Cutsem, MD, PhD, University Hospitals Leuven, Leuven, Belgium

Featured Topic

prIME Points™

This educational activity is designed for European surgical, radiation, and medical oncologists, gastroenterologists, and other healthcare providers involved in the management of patients with pancreatic cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe the genomic complexity and molecular heterogeneity of pancreatic cancer
  • Explain advances in imaging modalities of pancreatic cancer and recognize imaging criteria defining resectability
  • Identify multimodality treatment strategies for localized resectable, borderline, and unresectable pancreatic cancer
  • Select the most appropriate therapeutic approach for metastatic pancreatic ductal adenocarcinoma based on patient and disease characteristics, both in the first-line setting and beyond
  • Assess supportive care measures to ameliorate disease symptoms and treatment-related adverse events throughout the course of pancreatic cancer management
  • Describe emerging treatment strategies in pancreatic cancer, including the role of immunotherapy

This educational activity is supported by grants from Celgene and Shire.

Enduring Materials From a Certified Activity

This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Bali has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Bruns has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Cascinu has disclosed that he has received grants or research support from Celgene. He has also received honoraria or consultation fees from Bayer and has participated in a company-sponsored speaker’s bureau for Bayer and Lilly. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Chiorean has disclosed that she has received grants or research support from Boehringer Ingelheim, Celgene, Ignyta, and Stemline. She has also received support from Celgene and Genentech for participation in scientific advisory boards. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ellenrieder has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Macarulla has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Philip has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Prager has disclosed that he has received honoraria or consultation fees from Celgene and Shire. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Van Cutsem has disclosed that he has received grants or research support from Amgen, Bayer, Boehringer Ingelheim, Celgene, Lilly, MSD, Merck, Novartis, Ipsen, Roche, Sanofi, and Servier. He has also received honorarium or consultation fees from Bayer, Lilly, Roche, and Servier. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.